文献速递肝病

新型抗己糖激酶1抗体与原发性胆汁性胆管炎患者不良预后相关

Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

研究纳入254例原发性胆汁性胆管炎(PBC)患者,检测抗HK1、抗KLHL12、AMA、抗gp210和抗sp100抗体,评估抗体变化与临床结局的关系。抗HK1和抗KLHL12分别在46.1%和22.8%患者中检出,在常规PBC特异性抗体均阴性的患者中40%存在这两种抗体。抗HK1阳性患者无移植生存期和至肝失代偿时间显著更短(P=0.039;P=0.04)。

要点

  • 抗HK1和抗KLHL12在常规PBC抗体阴性患者中检出率分别为37.5%和40%。
  • 抗HK1阳性与无移植生存期及至肝失代偿时间显著缩短相关(P=0.039;P=0.04)。
  • 抗sp100阳性同样与无移植生存期及至肝失代偿时间显著缩短相关(P=0.01;P=0.007)。

核心结论

  • 抗HK1和抗KLHL12存在于40%经传统PBC特异性抗体检测为血清阴性的PBC患者中,这些新型抗体在疾病过程中保持相对稳定,抗HK1抗体与不良结局相关。

研究设计与样本

  • 研究纳入254例PBC患者(93.3%女性,51±12.3岁),检测抗HK1、抗KLHL12、AMA、抗gp210和抗sp100抗体,其中169例检测两次、49例检测三次,随访4.2(0.8-10.0)年。
  • 评估诊断时生化指标与临床特征、治疗应答、失代偿事件及肝相关死亡或移植。

主要发现

  • 抗HK1和抗KLHL12分别在46.1%和22.8%患者中检出,AMA阳性率93.7%,抗sp100阳性率26.4%,抗gp210阳性率21.3%。
  • 抗HK1和抗KLHL12阳性状态随时间变化的患者分别占13.3%和5.5%。
  • 抗HK1或抗KLHL12在AMA阴性患者中占37.5%,在AMA、抗gp210和抗sp100均阴性患者中占40%。
  • 抗HK1阳性患者无移植生存期(P=0.039)和至肝失代偿时间(P=0.04)显著更短,抗sp100阳性患者同样显著更短(P=0.01;P=0.007)。
  • AMA、抗KLHL12或抗gp210抗体阳性与生存及肝失代偿事件无显著变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Antibodies to hexokinase 1 (HK1) and kelch-like 12 (KLHL12) have been identified as potential biomarkers in primary biliary cholangitis (PBC), and this study assesses changes of these antibodies over time and if they are associated with clinical outcomes. METHODS: Two hundred fifty-four PBC patients (93.3% female, 51 ± 12.3 years old) were tested for anti-HK1 and anti-KLHL12, antimitochondrial (AMA), anti-gp210, and anti-sp100 antibodies. One hundred sixty-nine patients were tested twice and 49 three times within 4.2 (0.8-10.0) years. Biochemistry and clinical features at diagnosis, response to therapy, events of decompensation, and liver-related death or transplantation were evaluated. RESULTS: Anti-HK1 and anti-KLHL2 were detected in 46.1% and 22.8% patients, respectively. AMA were positive in 93.7%, anti-sp100 in 26.4%, and anti-gp210 in 21.3% of patients. Anti-HK1 and anti-KLHL12 positivity changed over time in 13.3% and 5.5% of patients, respectively. Anti-HK1 or anti-KLHL12 were present in 37.5% of AMA-negative patients, and in 40% of AMA, anti-gp210, and anti-sp100 negative. No significant differences were observed between those with or without HK1 and KLHL12 antibodies, but transplant-free survival and time to liver decompensation were significantly lower in patients anti-HK1 positive (P = 0.039; P = 0.04) and in those anti-sp100 positive (P = 0.01; P = 0.007). No changes in survival and events of liver decompensation were observed according to the positivity of AMA, anti-KLHL12, or anti-gp210 antibodies. DISCUSSION: HK1 and KLHL12 antibodies are present in 40% of PBC patients who are seronegative by the conventional PBC-specific antibodies. The novel antibodies remain rather steady during the course of the disease, and HK1 antibodies are associated with unfavourable outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Reig A, Norman GL, Garcia M, et al. Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis. Am J Gastroenterol. 2020. PMID: 32467507. doi:10.14309/ajg.0000000000000690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。